Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.44 |
| ▸ | MDM4 | O15151 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PPID | Q08752 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2115563 | 0.92 | ALDH1A1 (0.50) | MAPTALDH1A1PIN1TRPM8MDM4 | |
| SCHEMBL2115566 | 0.92 | ALDH1A1 (0.50) | MAPTALDH1A1PIN1TRPM8MDM4 | |
| SCHEMBL28619903 | 0.82 | ALDH1A1 (0.46) | MAPTALDH1A1PIN1TRPM8LMNA | |
| SCHEMBL28629284 | 0.82 | PIN1 (0.42) | MAPTALDH1A1PIN1LMNAMEN1 | |
| SCHEMBL2609721 | 0.82 | PIN1 (0.42) | MAPTALDH1A1PIN1LMNAMEN1 | |
| SCHEMBL3213534 | 0.82 | ALDH1A1 (0.55) | ALDH1A1PIN1TRPM8LMNAPOLB | |
| SCHEMBL2115838 | 0.81 | MEN1 (0.53) | MAPTALDH1A1PIN1TRPM8LMNA | |
| SCHEMBL9686760 | 0.81 | PIN1 (0.53) | ALDH1A1PIN1TRPM8LMNAPOLB | |
| SCHEMBL1964036 | 0.80 | HCAR2 (0.51) | MAPTALDH1A1PIN1LMNAMEN1 | |
| SCHEMBL1964039 | 0.80 | HCAR2 (0.51) | MAPTALDH1A1PIN1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11246850-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210315854-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | BIOGEN MA INC. | 2021-10-14 | — | — | US | disclosed |
| US-11129806-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-11007166-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-11007167-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10959972-B2 | Methods of treating multiple sclerosis | BIOGEN MA INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20210023040-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | BIOGEN MA INC. | 2021-01-28 | — | — | US | disclosed |
| US-20200345679-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | BIOGEN MA INC. | 2020-11-05 | — | — | US | disclosed |
| US-20190125710-A1 | Methods of Treating Multiple Sclerosis | BIOGEN MA INC. (US) | 2019-05-02 | — | — | US | disclosed |
| US-20180000770-A1 | Methods of Treating Multiple Sclerosis | BIOGEN MA INC (US) | 2018-01-04 | — | — | US | disclosed |
| US-8778991-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | XENOPORT, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | XENOPORT, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-8148414-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-8148414-B2 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use | XENOPORT, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| WO-2010022177-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11129806-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | MAPT 28/4885ALDH1A1 3424/4885PIN1 1935/4885 |
| US-20120157523-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | MAPT 1222/4885ALDH1A1 2050/4885PIN1 456/4885 |
| US-20190125710-A1 | Methods of Treating Multiple Sclerosis | FAH, FH, PML | MAPT 28/4885ALDH1A1 3424/4885PIN1 1935/4885 |
| US-20210023040-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | FAH, FH, PML | MAPT 28/4885ALDH1A1 3424/4885PIN1 1935/4885 |
| US-11007167-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | MAPT 28/4885ALDH1A1 3424/4885PIN1 1935/4885 |
| US-20120095003-A1 | METHODS OF USING PRODRUGS OF METHYL HYDROGEN FUMARATE AND PHARMACEUTICAL COMPOSITIONS THEREOF | FH, MGMT, BHMT2 | MAPT 1398/4885ALDH1A1 1970/4885PIN1 405/4885 |
| US-11007166-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | MAPT 28/4885ALDH1A1 3424/4885PIN1 1935/4885 |
| US-11246850-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | MAPT 28/4885ALDH1A1 3424/4885PIN1 1935/4885 |
| US-20210315854-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | FAH, FH, PML | MAPT 28/4885ALDH1A1 3424/4885PIN1 1935/4885 |
| US-20180000770-A1 | Methods of Treating Multiple Sclerosis | FAH, FH, PML | MAPT 28/4885ALDH1A1 3424/4885PIN1 1935/4885 |
| US-10959972-B2 | Methods of treating multiple sclerosis | FAH, FH, PML | MAPT 28/4885ALDH1A1 3424/4885PIN1 1935/4885 |
| US-20100048651-A1 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, MGMT, BHMT2 | MAPT 1222/4885ALDH1A1 2050/4885PIN1 456/4885 |
| US-20200345679-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS | FAH, FH, PML | MAPT 28/4885ALDH1A1 3424/4885PIN1 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.